Your browser doesn't support javascript.
loading
Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.
Yen, Fu-Shun; Wang, Shiow-Ing; Hsu, Chih-Cheng; Hwu, Chii-Min; Wei, James Cheng-Chung.
Affiliation
  • Yen FS; Dr Yen's Clinic, Taoyuan, Taiwan.
  • Wang SI; Center for Health Data Science, Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Hsu CC; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Hwu CM; Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan.
  • Wei JC; Department of Health Services Administration, China Medical University, Taichung, Taiwan.
JAMA Netw Open ; 7(6): e2416578, 2024 Jun 03.
Article in En | MEDLINE | ID: mdl-38865122
ABSTRACT
Importance Lupus nephritis is a major complication of systemic lupus erythematosus (SLE). Randomized clinical trials have shown nephroprotective and cardioprotective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is).

Objective:

To investigate whether the use of SGLT2is is associated with the onset and progression of lupus nephritis and other kidney and cardiac outcomes in patients with SLE and type 2 diabetes. Design, Setting, and

Participants:

This multicenter cohort study used the US Collaborative Network of the TriNetX clinical data platform to identify patients with SLE and type 2 diabetes from January 1, 2015, to December 31, 2022. Data collection and analysis were conducted in September 2023. Exposures Individuals were categorized into 2 groups by SGLT2i use or nonuse with 11 propensity score matching. Main Outcomes and

Measures:

The Kaplan-Meier method and Cox proportional hazards regression models were used to calculate the 5-year adjusted hazard ratios (AHRs) of lupus nephritis, dialysis, kidney transplant, heart failure, and mortality for the 2 groups.

Results:

From 31 790 eligible participants, 1775 matched pairs of SGLT2i users and nonusers (N = 3550) were selected based on propensity scores. The mean (SD) age of matched participants was 56.8 (11.6) years, and 3012 (84.8%) were women. SGLT2i users had a significantly lower risk of lupus nephritis (AHR, 0.55; 95% CI, 0.40-0.77), dialysis (AHR, 0.29; 95% CI, 0.17-0.48), kidney transplant (AHR, 0.14; 95% CI, 0.03-0.62), heart failure (AHR, 0.65; 95% CI, 0.53-0.78), and all-cause mortality (AHR, 0.35; 95% CI, 0.26-0.47) than SGLT2i nonusers. Conclusions and Relevance In this cohort study of patients with SLE and type 2 diabetes, SGLT2i users had a significantly lower risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality than nonusers. The findings suggest that SGLT2is may provide some nephroprotective and cardioprotective benefits.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Lupus Erythematosus, Systemic Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Netw Open Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Nephritis / Diabetes Mellitus, Type 2 / Sodium-Glucose Transporter 2 Inhibitors / Lupus Erythematosus, Systemic Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Netw Open Year: 2024 Document type: Article Affiliation country: